Skip to main content
Top
Published in:

25-05-2024 | Hypersensitivity Pneumonitis Due to Organic Dust | REVIEW

Hypersensitivity Pneumonitis: A Silent Epidemic?

Authors: Kavitha Selvan, Cathryn T. Lee

Published in: Current Pulmonology Reports | Issue 3/2024

Login to get access

Abstract

Purpose of Review

Hypersensitivity pneumonitis (HP), along with interstitial lung disease as a whole, is a disorder with rising incidence, morbidity, and potentially mortality. Herein we review latest updates on epidemiology, environmental exposures, diagnosis, and treatment of this devastating disorder.

Recent Findings

Both the American Thoracic Society as well as the American College of Chest Physicians have recently released diagnostic guidelines for HP, offering an opportunity to standardize patient care and research in the coming years. Novel exposures associated with HP highlight its ever-changing epidemiology amidst a world threatened by climate change.

Summary

As diagnosis and treatment become more standardized for hypersensitivity pneumonitis, the varied presentations, exposures, and outcomes of the disorder lend itself to future research regarding both novel threats as well as precision approaches to care for patients with this heterogenous and incompletely understood disease.
Literature
2.
go back to reference Fernández Pérez ER, Kong AM, Raimundo K, Koelsch TL, Kulkarni R, Cole AL. Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis. Annals ATS. 2018;15:460–9.CrossRef Fernández Pérez ER, Kong AM, Raimundo K, Koelsch TL, Kulkarni R, Cole AL. Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis. Annals ATS. 2018;15:460–9.CrossRef
3.
go back to reference Copeland CR, Donnelly EF, Mehrad M, Ding G, Markin CR, Douglas K, et al. The association between exposures and disease characteristics in familial pulmonary fibrosis. Ann Am Thorac Soc. 2022;19:2003–12.PubMedPubMedCentralCrossRef Copeland CR, Donnelly EF, Mehrad M, Ding G, Markin CR, Douglas K, et al. The association between exposures and disease characteristics in familial pulmonary fibrosis. Ann Am Thorac Soc. 2022;19:2003–12.PubMedPubMedCentralCrossRef
4.
go back to reference Cano-Jiménez E, Villar Gómez A, Velez Segovia E, Aburto Barrenechea M, Sellarés Torres J, Francesqui J, et al. Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study. ERJ Open Res. 2024;10:00405–2023.PubMedPubMedCentralCrossRef Cano-Jiménez E, Villar Gómez A, Velez Segovia E, Aburto Barrenechea M, Sellarés Torres J, Francesqui J, et al. Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study. ERJ Open Res. 2024;10:00405–2023.PubMedPubMedCentralCrossRef
5.
go back to reference Yamashita S, Okamoto T, Kawahara T, Tateishi T, Anzai T, Takahashi K, et al. Database analysis of hypersensitivity pneumonitis in Japan. Respir Investig. 2023;61:172–80.PubMedCrossRef Yamashita S, Okamoto T, Kawahara T, Tateishi T, Anzai T, Takahashi K, et al. Database analysis of hypersensitivity pneumonitis in Japan. Respir Investig. 2023;61:172–80.PubMedCrossRef
6.
go back to reference Jung HI, Nam DR, You S-H, Jung J-W, Gu K-M, Jung S-Y. Nationwide study of the epidemiology, diagnosis, and treatment of hypersensitivity pneumonitis in Korea. J Korean Med Sci. 2024;39:e96.PubMedPubMedCentralCrossRef Jung HI, Nam DR, You S-H, Jung J-W, Gu K-M, Jung S-Y. Nationwide study of the epidemiology, diagnosis, and treatment of hypersensitivity pneumonitis in Korea. J Korean Med Sci. 2024;39:e96.PubMedPubMedCentralCrossRef
7.
go back to reference Thomeer M, Demedts M, Vandeurzen K, VRGT Working Group on Interstitial Lung Diseases. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001;56:163–72.PubMedCrossRef Thomeer M, Demedts M, Vandeurzen K, VRGT Working Group on Interstitial Lung Diseases. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001;56:163–72.PubMedCrossRef
8.
go back to reference Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, Sanyal S, Brillet P-Y, Brauner M, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. 2017;50:1602419.PubMedCrossRef Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, Sanyal S, Brillet P-Y, Brauner M, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. 2017;50:1602419.PubMedCrossRef
9.
go back to reference Dhooria S, Sehgal IS, Agarwal R, Muthu V, Prasad KT, Kathirvel S, et al. Incidence, prevalence, and national burden of interstitial lung diseases in India: Estimates from two studies of 3089 subjects. PLoS ONE. 2022;17:e0271665.PubMedPubMedCentralCrossRef Dhooria S, Sehgal IS, Agarwal R, Muthu V, Prasad KT, Kathirvel S, et al. Incidence, prevalence, and national burden of interstitial lung diseases in India: Estimates from two studies of 3089 subjects. PLoS ONE. 2022;17:e0271665.PubMedPubMedCentralCrossRef
10.
go back to reference Singh S, Bairwa M, Collins B, Sharma B, Joshi J, Talwar D, et al. Survival predictors of interstitial lung disease in India: Follow-up of Interstitial Lung Disease India registry. Lung India. 2021;38:5–11.PubMedCrossRef Singh S, Bairwa M, Collins B, Sharma B, Joshi J, Talwar D, et al. Survival predictors of interstitial lung disease in India: Follow-up of Interstitial Lung Disease India registry. Lung India. 2021;38:5–11.PubMedCrossRef
11.
go back to reference • Kaul B, Cottin V, Collard HR, Valenzuela C. Variability in global prevalence of interstitial lung disease. Front Med (Lausanne). 2021;8:751181. Comprehensive review of the comparative epidemiology of HP across the globe.PubMedCrossRef • Kaul B, Cottin V, Collard HR, Valenzuela C. Variability in global prevalence of interstitial lung disease. Front Med (Lausanne). 2021;8:751181. Comprehensive review of the comparative epidemiology of HP across the globe.PubMedCrossRef
12.
go back to reference Vasakova M, Selman M, Morell F, Sterclova M, Molina-Molina M, Raghu G. Hypersensitivity pneumonitis: Current concepts of pathogenesis and potential targets for treatment. Am J Respir Crit Care Med. 2019;200:301–8.PubMedCrossRef Vasakova M, Selman M, Morell F, Sterclova M, Molina-Molina M, Raghu G. Hypersensitivity pneumonitis: Current concepts of pathogenesis and potential targets for treatment. Am J Respir Crit Care Med. 2019;200:301–8.PubMedCrossRef
13.
go back to reference Selman M, Pardo A, King TE. Hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2012;186:314–24.PubMedCrossRef Selman M, Pardo A, King TE. Hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2012;186:314–24.PubMedCrossRef
14.
go back to reference Joshi AD, Fong DJ, Oak SR, Trujillo G, Flaherty KR, Martinez FJ, et al. Interleukin-17-mediated immunopathogenesis in experimental hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2009;179:705–16.PubMedCrossRef Joshi AD, Fong DJ, Oak SR, Trujillo G, Flaherty KR, Martinez FJ, et al. Interleukin-17-mediated immunopathogenesis in experimental hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2009;179:705–16.PubMedCrossRef
15.
go back to reference Agostini C, Calabrese F, Poletti V, Marcer G, Facco M, Miorin M, et al. CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis. Respir Res. 2005;6:20.PubMedPubMedCentralCrossRef Agostini C, Calabrese F, Poletti V, Marcer G, Facco M, Miorin M, et al. CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis. Respir Res. 2005;6:20.PubMedPubMedCentralCrossRef
16.
go back to reference Buendia-Roldan I, Fernandez R, Mejia M, Juarez F, Ramirez-Martinez G, Montes E, et al. Risk factors associated with the development of interstitial lung abnormalities. Eur Respir J. 2021;58:2003005.PubMedCrossRef Buendia-Roldan I, Fernandez R, Mejia M, Juarez F, Ramirez-Martinez G, Montes E, et al. Risk factors associated with the development of interstitial lung abnormalities. Eur Respir J. 2021;58:2003005.PubMedCrossRef
17.
go back to reference Adegunsoye A, Oldham JM, Demchuk C, Montner S, Vij R, Strek ME. Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features. Respir Med. 2016;114:53–60.PubMedPubMedCentralCrossRef Adegunsoye A, Oldham JM, Demchuk C, Montner S, Vij R, Strek ME. Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features. Respir Med. 2016;114:53–60.PubMedPubMedCentralCrossRef
18.
go back to reference Kalra SS, Jaber JF, Alzghoul B, Jansen B, Innabi A, Tran AB, et al. Hypersensitivity pneumonitis with and without autoimmune features: a clinical comparative analysis. Lung. 2022;200:763–71.PubMedCrossRef Kalra SS, Jaber JF, Alzghoul B, Jansen B, Innabi A, Tran AB, et al. Hypersensitivity pneumonitis with and without autoimmune features: a clinical comparative analysis. Lung. 2022;200:763–71.PubMedCrossRef
19.
go back to reference •• Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis in adults: an official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020;202:e36–69. Clinical practice guidelines published in 2020 by the ATS/JRS/ALAT on the diagnosis of HP.PubMedPubMedCentralCrossRef •• Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis in adults: an official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020;202:e36–69. Clinical practice guidelines published in 2020 by the ATS/JRS/ALAT on the diagnosis of HP.PubMedPubMedCentralCrossRef
20.
go back to reference •• Pérez ERF, Travis WD, Lynch DA, Brown KK, Johannson KA, Selman M, et al. Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report. Chest. 2021;160:e97-156. Expert guidelines published in 2021 by the CHEST Foundation on the diagnosis and management of HP.CrossRef •• Pérez ERF, Travis WD, Lynch DA, Brown KK, Johannson KA, Selman M, et al. Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report. Chest. 2021;160:e97-156. Expert guidelines published in 2021 by the CHEST Foundation on the diagnosis and management of HP.CrossRef
21.
go back to reference Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: Perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196:680–9.PubMedCrossRef Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: Perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196:680–9.PubMedCrossRef
22.
go back to reference Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go. Am J Respir Crit Care Med. 2017;196:690–9.PubMedPubMedCentralCrossRef Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go. Am J Respir Crit Care Med. 2017;196:690–9.PubMedPubMedCentralCrossRef
23.
go back to reference Blanc PD, Annesi-Maesano I, Balmes JR, Cummings KJ, Fishwick D, Miedinger D, et al. The occupational burden of nonmalignant respiratory diseases. An official american thoracic society and european respiratory society statement. Am J Respir Crit Care Med. 2019;199:1312–34.PubMedPubMedCentralCrossRef Blanc PD, Annesi-Maesano I, Balmes JR, Cummings KJ, Fishwick D, Miedinger D, et al. The occupational burden of nonmalignant respiratory diseases. An official american thoracic society and european respiratory society statement. Am J Respir Crit Care Med. 2019;199:1312–34.PubMedPubMedCentralCrossRef
24.
go back to reference Lee CT, Adegunsoye A, Chung JH, Ventura IB, Jablonski R, Montner S, et al. Characteristics and prevalence of domestic and occupational inhalational exposures across interstitial lung diseases. Chest. 2021;160:209–18.PubMedPubMedCentralCrossRef Lee CT, Adegunsoye A, Chung JH, Ventura IB, Jablonski R, Montner S, et al. Characteristics and prevalence of domestic and occupational inhalational exposures across interstitial lung diseases. Chest. 2021;160:209–18.PubMedPubMedCentralCrossRef
25.
go back to reference Lee CT, Strek ME, Adegunsoye A, Wong AW, Assayag D, Cox G, et al. Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis. Respirology. 2022;27:635–44.PubMedPubMedCentralCrossRef Lee CT, Strek ME, Adegunsoye A, Wong AW, Assayag D, Cox G, et al. Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis. Respirology. 2022;27:635–44.PubMedPubMedCentralCrossRef
26.
go back to reference Petnak T, Moua T. Exposure assessment in hypersensitivity pneumonitis: a comprehensive review and proposed screening questionnaire. ERJ Open Res. 2020;6(3):00230–2020.PubMedPubMedCentralCrossRef Petnak T, Moua T. Exposure assessment in hypersensitivity pneumonitis: a comprehensive review and proposed screening questionnaire. ERJ Open Res. 2020;6(3):00230–2020.PubMedPubMedCentralCrossRef
27.
go back to reference Walters GI, Mokhlis JM, Moore VC, Robertson AS, Burge GA, Bhomra PS, et al. Characteristics of hypersensitivity pneumonitis diagnosed by interstitial and occupational lung disease multi-disciplinary team consensus. Respir Med. 2019;155:19–25.PubMedCrossRef Walters GI, Mokhlis JM, Moore VC, Robertson AS, Burge GA, Bhomra PS, et al. Characteristics of hypersensitivity pneumonitis diagnosed by interstitial and occupational lung disease multi-disciplinary team consensus. Respir Med. 2019;155:19–25.PubMedCrossRef
28.
go back to reference Moran-Mendoza O, Aldhaheri S, Black CJA, Clements-Baker M, Khalil M, Boag A. Mold in foam pillows and mattresses: a novel cause of hypersensitivity pneumonitis. Chest. 2021;160:e259–63.PubMedCrossRef Moran-Mendoza O, Aldhaheri S, Black CJA, Clements-Baker M, Khalil M, Boag A. Mold in foam pillows and mattresses: a novel cause of hypersensitivity pneumonitis. Chest. 2021;160:e259–63.PubMedCrossRef
30.
go back to reference Walters GI, Trotter S, Sinha B, Richmond Z, Burge PS. Biopsy-proven hypersensitivity pneumonitis caused by a fluorocarbon waterproofing spray. Occup Med (Lond). 2017;67:308–10.PubMedCrossRef Walters GI, Trotter S, Sinha B, Richmond Z, Burge PS. Biopsy-proven hypersensitivity pneumonitis caused by a fluorocarbon waterproofing spray. Occup Med (Lond). 2017;67:308–10.PubMedCrossRef
31.
go back to reference Walters GI, Huntley CC. Novel occupational causes of hypersensitivity pneumonitis. Curr Opin Allergy Clin Immunol. 2023;23:85–91.PubMedCrossRef Walters GI, Huntley CC. Novel occupational causes of hypersensitivity pneumonitis. Curr Opin Allergy Clin Immunol. 2023;23:85–91.PubMedCrossRef
32.
go back to reference Kutsuzawa N, Takihara T, Shiraishi Y, Kajiwara H, Imanishi T, Fukutomi Y, et al. Occupational hypersensitivity pneumonitis in a Japanese citrus farmer. Intern Med. 2021;60:3581–4.PubMedPubMedCentralCrossRef Kutsuzawa N, Takihara T, Shiraishi Y, Kajiwara H, Imanishi T, Fukutomi Y, et al. Occupational hypersensitivity pneumonitis in a Japanese citrus farmer. Intern Med. 2021;60:3581–4.PubMedPubMedCentralCrossRef
33.
go back to reference Ishiguro T, Kawai S, Kojima A, Shimizu Y, Kamei K, Takayanagi N. Occupational hypersensitivity pneumonitis in a koji brewer. Clin Case Rep. 2018;6:461–4.PubMedPubMedCentralCrossRef Ishiguro T, Kawai S, Kojima A, Shimizu Y, Kamei K, Takayanagi N. Occupational hypersensitivity pneumonitis in a koji brewer. Clin Case Rep. 2018;6:461–4.PubMedPubMedCentralCrossRef
34.
go back to reference Armentia A, Fernández S, San Miguel Rodríguez A, San Miguel Hernández A, Corell A, Gayoso M. Occupational hypersensitivity pneumonitis caused by fossil-containing rocks. Clinica Chimica Acta. 2022;524:139–45.CrossRef Armentia A, Fernández S, San Miguel Rodríguez A, San Miguel Hernández A, Corell A, Gayoso M. Occupational hypersensitivity pneumonitis caused by fossil-containing rocks. Clinica Chimica Acta. 2022;524:139–45.CrossRef
35.
go back to reference Barnes H, Morisset J, Molyneaux P, Westall G, Glaspole I, Collard HR, et al. A systematically derived exposure assessment instrument for chronic hypersensitivity pneumonitis. Chest. 2020;157:1506–12.PubMedPubMedCentralCrossRef Barnes H, Morisset J, Molyneaux P, Westall G, Glaspole I, Collard HR, et al. A systematically derived exposure assessment instrument for chronic hypersensitivity pneumonitis. Chest. 2020;157:1506–12.PubMedPubMedCentralCrossRef
36.
go back to reference Barnes H, Troy L, Lee CT, Sperling A, Strek M, Glaspole I. Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment. Allergy. 2022;77(2):442–53.PubMedCrossRef Barnes H, Troy L, Lee CT, Sperling A, Strek M, Glaspole I. Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment. Allergy. 2022;77(2):442–53.PubMedCrossRef
37.
go back to reference Jenkins AR, Chua A, Chami H, Diaz-Mendoza J, Duggal A, Knight S, et al. Questionnaires or serum immunoglobulin G testing in the diagnosis of hypersensitivity pneumonitis among patients with interstitial lung disease. Ann Am Thorac Soc. 2021;18:130–47.PubMedCrossRef Jenkins AR, Chua A, Chami H, Diaz-Mendoza J, Duggal A, Knight S, et al. Questionnaires or serum immunoglobulin G testing in the diagnosis of hypersensitivity pneumonitis among patients with interstitial lung disease. Ann Am Thorac Soc. 2021;18:130–47.PubMedCrossRef
38.
go back to reference Johannson KA, Barnes H, Bellanger A-P, Dalphin J-C, Fernández Pérez ER, Flaherty KR, et al. Exposure assessment tools for hypersensitivity pneumonitis. An official american thoracic society workshop report. Annals ATS. 2020;17:1501–9.CrossRef Johannson KA, Barnes H, Bellanger A-P, Dalphin J-C, Fernández Pérez ER, Flaherty KR, et al. Exposure assessment tools for hypersensitivity pneumonitis. An official american thoracic society workshop report. Annals ATS. 2020;17:1501–9.CrossRef
39.
go back to reference Demirkol B, Satici C, Tanriverdi E, Eren R, Altundas Hatman E, Yardimci HA, et al. Serum specific antibodies do not seem to have an additional role in the diagnosis of hypersensitivity pneumonitis. Med Lav. 2023;114:e2023042.PubMedPubMedCentral Demirkol B, Satici C, Tanriverdi E, Eren R, Altundas Hatman E, Yardimci HA, et al. Serum specific antibodies do not seem to have an additional role in the diagnosis of hypersensitivity pneumonitis. Med Lav. 2023;114:e2023042.PubMedPubMedCentral
40.
go back to reference Chelala L, Adegunsoye A, Cody BA, Husain AN, Chung JH. Updated imaging classification of hypersensitivity pneumonitis. Radiol Clin North Am. 2022;60:901–13.PubMedCrossRef Chelala L, Adegunsoye A, Cody BA, Husain AN, Chung JH. Updated imaging classification of hypersensitivity pneumonitis. Radiol Clin North Am. 2022;60:901–13.PubMedCrossRef
41.
go back to reference Brixey AG, Oh AS, Alsamarraie A, Chung JH. Pictorial review of fibrotic interstitial lung disease on high-resolution CT scan and updated classification. Chest. 2024;S0012–3692(23):05829–34. Brixey AG, Oh AS, Alsamarraie A, Chung JH. Pictorial review of fibrotic interstitial lung disease on high-resolution CT scan and updated classification. Chest. 2024;S0012–3692(23):05829–34.
42.
go back to reference Marinescu D-C, Hague CJ, Muller NL, Murphy D, Churg A, Wright JL, et al. Integration and application of radiologic patterns from clinical practice guidelines on idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis. Chest. 2023;164:1466–75.PubMedCrossRef Marinescu D-C, Hague CJ, Muller NL, Murphy D, Churg A, Wright JL, et al. Integration and application of radiologic patterns from clinical practice guidelines on idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis. Chest. 2023;164:1466–75.PubMedCrossRef
44.
go back to reference Churg A, Bilawich A, Wright JL. Pathology of chronic hypersensitivity pneumonitis what is it? what are the diagnostic criteria? why do we care? Arch Pathol Lab Med. 2018;142:109–19.PubMedCrossRef Churg A, Bilawich A, Wright JL. Pathology of chronic hypersensitivity pneumonitis what is it? what are the diagnostic criteria? why do we care? Arch Pathol Lab Med. 2018;142:109–19.PubMedCrossRef
45.
go back to reference Castonguay MC, Ryu JH, Yi ES, Tazelaar HD. Granulomas and giant cells in hypersensitivity pneumonitis. Hum Pathol. 2015;46:607–13.PubMedCrossRef Castonguay MC, Ryu JH, Yi ES, Tazelaar HD. Granulomas and giant cells in hypersensitivity pneumonitis. Hum Pathol. 2015;46:607–13.PubMedCrossRef
46.
go back to reference Chiba S, Tsuchiya K, Akashi T, Ishizuka M, Okamoto T, Furusawa H, et al. Chronic hypersensitivity pneumonitis with a usual interstitial pneumonia-like pattern: Correlation between histopathologic and clinical findings. Chest. 2016;149:1473–81.PubMedCrossRef Chiba S, Tsuchiya K, Akashi T, Ishizuka M, Okamoto T, Furusawa H, et al. Chronic hypersensitivity pneumonitis with a usual interstitial pneumonia-like pattern: Correlation between histopathologic and clinical findings. Chest. 2016;149:1473–81.PubMedCrossRef
47.
go back to reference Botelho AB, Ferreira RG, Coletta ENAM, Cerezoli MT, Martins RB, Gomes PS, et al. Transbronchial biopsy in chronic hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis. 2021;38:e2021018.PubMedPubMedCentral Botelho AB, Ferreira RG, Coletta ENAM, Cerezoli MT, Martins RB, Gomes PS, et al. Transbronchial biopsy in chronic hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis. 2021;38:e2021018.PubMedPubMedCentral
48.
go back to reference Troy LK, Grainge C, Corte TJ, Williamson JP, Vallely MP, Cooper WA, et al. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med. 2020;8:171–81.PubMedCrossRef Troy LK, Grainge C, Corte TJ, Williamson JP, Vallely MP, Cooper WA, et al. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med. 2020;8:171–81.PubMedCrossRef
49.
go back to reference Hetzel J, Wells AU, Costabel U, Colby TV, Walsh SLF, Verschakelen J, et al. Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicentre trial. Eur Respir J. 2020;56:1901520.PubMedCrossRef Hetzel J, Wells AU, Costabel U, Colby TV, Walsh SLF, Verschakelen J, et al. Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicentre trial. Eur Respir J. 2020;56:1901520.PubMedCrossRef
51.
go back to reference Fernández Pérez ER, Swigris JJ, Forssén AV, Tourin O, Solomon JJ, Huie TJ, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013;144:1644–51.PubMedPubMedCentralCrossRef Fernández Pérez ER, Swigris JJ, Forssén AV, Tourin O, Solomon JJ, Huie TJ, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013;144:1644–51.PubMedPubMedCentralCrossRef
52.
go back to reference Aronson KI, O’Beirne R, Martinez FJ, Safford MM. Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States. Respir Res. 2021;22:225.PubMedPubMedCentralCrossRef Aronson KI, O’Beirne R, Martinez FJ, Safford MM. Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States. Respir Res. 2021;22:225.PubMedPubMedCentralCrossRef
53.
go back to reference Pitre T, Kawano-Dourado L, Kachkovski GV, Leung D, Leung G, Desai K, et al. Systemic corticosteroids in fibrotic lung disease: a systematic review and meta-analysis. BMJ Open Respir Res. 2023;10:e002008.PubMedPubMedCentralCrossRef Pitre T, Kawano-Dourado L, Kachkovski GV, Leung D, Leung G, Desai K, et al. Systemic corticosteroids in fibrotic lung disease: a systematic review and meta-analysis. BMJ Open Respir Res. 2023;10:e002008.PubMedPubMedCentralCrossRef
54.
go back to reference De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med. 2018;8:14.PubMedPubMedCentralCrossRef De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med. 2018;8:14.PubMedPubMedCentralCrossRef
55.
go back to reference De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, et al. Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. Eur Respir J. 2020;55:1901983.PubMedCrossRef De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, et al. Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. Eur Respir J. 2020;55:1901983.PubMedCrossRef
56.
go back to reference Mullin ML, Fernandez G, Marinescu D-C, Zheng B, Wong AW, Assayag D, et al. Impact of antigen exposure on outcomes and treatment response in fibrotic hypersensitivity pneumonitis. Chest. 2023;S0012–3692(23):05933. Mullin ML, Fernandez G, Marinescu D-C, Zheng B, Wong AW, Assayag D, et al. Impact of antigen exposure on outcomes and treatment response in fibrotic hypersensitivity pneumonitis. Chest. 2023;S0012–3692(23):05933.
57.
go back to reference Zhang D, Adegunsoye A, Oldham JM, Kozlitina J, Garcia N, Poonawalla M, et al. Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. Eur Respir J. 2023;62:2300441.PubMedPubMedCentralCrossRef Zhang D, Adegunsoye A, Oldham JM, Kozlitina J, Garcia N, Poonawalla M, et al. Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. Eur Respir J. 2023;62:2300441.PubMedPubMedCentralCrossRef
58.
go back to reference Morisset J, Johannson KA, Vittinghoff E, Aravena C, Elicker BM, Jones KD, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2017;151:619–25.PubMedCrossRef Morisset J, Johannson KA, Vittinghoff E, Aravena C, Elicker BM, Jones KD, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2017;151:619–25.PubMedCrossRef
59.
go back to reference Fiddler CA, Simler N, Thillai M, Parfrey H. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis-A single-centre experience. Clin Respir J. 2019;13:791–4.PubMedCrossRef Fiddler CA, Simler N, Thillai M, Parfrey H. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis-A single-centre experience. Clin Respir J. 2019;13:791–4.PubMedCrossRef
60.
go back to reference Adegunsoye A, Oldham JM, Fernández Pérez ER, Hamblin M, Patel N, Tener M, et al. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res. 2017;3:00016–2017.PubMedPubMedCentralCrossRef Adegunsoye A, Oldham JM, Fernández Pérez ER, Hamblin M, Patel N, Tener M, et al. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res. 2017;3:00016–2017.PubMedPubMedCentralCrossRef
61.
go back to reference Ferreira M, Borie R, Crestani B, Rigaud P, Wemeau L, Israel-Biet D, et al. Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study. Respir Med. 2020;172: 106146.PubMedCrossRef Ferreira M, Borie R, Crestani B, Rigaud P, Wemeau L, Israel-Biet D, et al. Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study. Respir Med. 2020;172: 106146.PubMedCrossRef
62.
go back to reference Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718–27.PubMedCrossRef Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718–27.PubMedCrossRef
63.
go back to reference Fernández Pérez ER, Crooks JL, Lynch DA, Humphries SM, Koelsch TL, Swigris JJ, et al. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax. 2023;78:1097–104.PubMedCrossRef Fernández Pérez ER, Crooks JL, Lynch DA, Humphries SM, Koelsch TL, Swigris JJ, et al. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax. 2023;78:1097–104.PubMedCrossRef
64.
go back to reference Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18–47.PubMedPubMedCentralCrossRef Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18–47.PubMedPubMedCentralCrossRef
65.
go back to reference Johannson KA, Kolb M, Fisher JH, Walsh SLF. Progressive pulmonary fibrosis: Putting the cart before the horse. Am J Respir Crit Care Med. 2022;206:1294–5.PubMedPubMedCentralCrossRef Johannson KA, Kolb M, Fisher JH, Walsh SLF. Progressive pulmonary fibrosis: Putting the cart before the horse. Am J Respir Crit Care Med. 2022;206:1294–5.PubMedPubMedCentralCrossRef
66.
go back to reference Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S, et al. Validation of proposed criteria for progressive pulmonary fibrosis. Am J Respir Crit Care Med. 2023;207:69–76.PubMedCrossRef Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S, et al. Validation of proposed criteria for progressive pulmonary fibrosis. Am J Respir Crit Care Med. 2023;207:69–76.PubMedCrossRef
68.
go back to reference Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60:2102571.PubMedCrossRef Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60:2102571.PubMedCrossRef
70.
71.
go back to reference Petnak T, Cheungpasitporn W, Thongprayoon C, Sodsri T, Tangpanithandee S, Moua T. Phenotypic subtypes of fibrotic hypersensitivity pneumonitis identified by machine learning consensus clustering analysis. Respir Res. 2024;25:41.PubMedPubMedCentralCrossRef Petnak T, Cheungpasitporn W, Thongprayoon C, Sodsri T, Tangpanithandee S, Moua T. Phenotypic subtypes of fibrotic hypersensitivity pneumonitis identified by machine learning consensus clustering analysis. Respir Res. 2024;25:41.PubMedPubMedCentralCrossRef
72.
go back to reference Fernández Pérez ER, Leach SM, Vestal B. Rationale and design of the prognostic transcriptomic signature in fibrotic hypersensitivity pneumonitis (PREDICT) study. ERJ Open Res. 2024;10:00625–2023.PubMedPubMedCentralCrossRef Fernández Pérez ER, Leach SM, Vestal B. Rationale and design of the prognostic transcriptomic signature in fibrotic hypersensitivity pneumonitis (PREDICT) study. ERJ Open Res. 2024;10:00625–2023.PubMedPubMedCentralCrossRef
73.
go back to reference Kespohl S, Riebesehl J, Grüner J, Raulf M. Impact of climate change on wood and woodworkers-Cryptostroma corticale (sooty bark disease): A risk factor for trees and exposed employees. Front Public Health. 2022;10: 973686.PubMedPubMedCentralCrossRef Kespohl S, Riebesehl J, Grüner J, Raulf M. Impact of climate change on wood and woodworkers-Cryptostroma corticale (sooty bark disease): A risk factor for trees and exposed employees. Front Public Health. 2022;10: 973686.PubMedPubMedCentralCrossRef
74.
go back to reference Fernández Pérez ER, Sprunger DB, Ratanawatkul P, Maier LA, Huie TJ, Swigris JJ, et al. Increasing hypersensitivity pneumonitis–related mortality in the United States from 1988 to 2016. Am J Respir Crit Care Med. 2019;199:1284–7.PubMedCrossRef Fernández Pérez ER, Sprunger DB, Ratanawatkul P, Maier LA, Huie TJ, Swigris JJ, et al. Increasing hypersensitivity pneumonitis–related mortality in the United States from 1988 to 2016. Am J Respir Crit Care Med. 2019;199:1284–7.PubMedCrossRef
Metadata
Title
Hypersensitivity Pneumonitis: A Silent Epidemic?
Authors
Kavitha Selvan
Cathryn T. Lee
Publication date
25-05-2024
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 3/2024
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-024-00354-z

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more